BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor developed from a hit identi...
Multi-year program supports development of disposable molecular diagnostic platforms for point-of-care, field-use, and emergency response settings ...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it has achieved ...
The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response. Hepatitis D affects nearly 12 million o...
First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust ZI-MA4-1 is the world’s first MAGE-A4-targe...
AI hasn’t taken over clinical trials. It’s taken over the parts of clinical trials nobody wanted to do manually in the first place. Clinicians ...
In 2024 alone, the FDA approved 50 novel therapies, supported by about 31,000 participants in pivotal trials. This is a powerful base of evidence, but it i...
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena admini...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment...
BriaCell is advancing a new generation of cancer immunotherapies designed to improve outcomes for patients with metastatic breast cancer and other solid tu...
SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing...
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared t...
Keenova Therapeutics plc announced positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the ...
Vaxart, Inc. announced topline data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the Company&r...
© 2026 Biopharma Boardroom. All Rights Reserved.
